C. Robert, G. V. Long, B. Brady, C. Dutriaux, M. Maio et al., Nivolumab in previously untreated melanoma without BRAF mutation, N Engl J Med, vol.22, pp.320-330, 2015.

J. S. Weber, S. P. Angelo, D. Minor, F. S. Hodi, R. Gutzmer et al., Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial, Lancet Oncol, vol.16, pp.375-384, 2015.

A. I. Daud, J. D. Wolchok, C. Robert, W. Hwu, J. S. Weber et al., Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma, J Clin Oncol, vol.34, pp.4102-4109, 2016.

J. M. Zaretsky, A. Garcia-diaz, D. S. Shin, H. Escuin-ordinas, W. Hugo et al., Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl www.medicaljournals.se/acta, J Med, vol.375, pp.819-829, 2016.

S. P. Patel and R. Kurzrock, PD-L1 expression as a predictive biomarker in cancer immunotherapy, Mol Cancer Ther, vol.14, pp.847-856, 2015.

S. Diem, B. Kasenda, L. Spain, J. Martin-liberal, R. Marconcini et al., Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma, Br J Cancer, vol.114, pp.256-261, 2016.

Y. Nakamura, S. Kitano, A. Takahashi, A. Tsutsumida, K. Namikawa et al., Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy, Oncotarget, vol.7, pp.77404-77415, 2016.

A. Martens, K. Wistuba-hamprecht, G. Foppen, M. Yuan, J. Postow et al., Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab, Clin Cancer Res, vol.22, pp.2908-2918, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01409624

B. Weide, A. Martens, J. C. Hassel, C. Berking, M. A. Postow et al., Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab, Clin Cancer Res, vol.22, pp.5487-5496, 2016.

J. Zaragoza, A. Caille, N. Beneton, G. Bens, F. Christiann et al., High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma, Br J Dermatol, vol.174, pp.146-151, 2016.

P. F. Ferrucci, P. A. Ascierto, J. Pigozzo, D. Vecchio, M. Maio et al., Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab, Ann Oncol, vol.27, pp.732-738, 2016.

C. M. Balch, J. E. Gershenwald, S. Soong, J. F. Thompson, M. B. Atkins et al., Final version of 2009 AJCC melanoma staging and classification, J Clin Oncol, vol.27, pp.6199-6206, 2009.

J. D. Wolchok, A. Hoos, S. O'day, J. S. Weber, O. Hamid et al., Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria, Clin Cancer Res, vol.15, pp.7412-7420, 2009.

D. Hanahan and R. A. Weinberg, Hallmarks of cancer: the next generation, Cell, vol.144, pp.646-674, 2011.

S. Singh, J. Himler, C. I. Nagel, and K. Resnick, The prognostic value of baseline lymphocyte, neutrophil, and monocyte counts in locally advanced cervical carcinoma treated with radiation, Obstet Gynecol Int, p.8584605, 2017.

C. Botta, V. Barbieri, D. Ciliberto, A. Rossi, D. Rocco et al., Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients, Cancer Biol Ther, vol.14, pp.469-475, 2013.

S. I. Gutman, M. Piper, M. D. Grant, E. Basch, D. M. Oliansky et al., Agency for Healthcare Research and Quality (US), 2013.

A. From,